Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Daré Bioscience (DARE) Stock Price & Analysis
1,788 Followers
DARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.05 - $13.58
Previous Close$3.54
Volume36.21K
Average Volume (3M)51.76K
Market Cap
$31.04M
Enterprise Value$27.86M
Total Cash (Recent Filing)$3.60M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 08, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding101,092,900
10 Day Avg. Volume292,092
30 Day Avg. Volume51,756
Standard Deviation0.23
R-Squared0.10
Alpha-0.00810
Financial Highlights & Ratios
Price to Book (P/B)-3.99
Price to Sales (P/S)15.64
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.61
Enterprise Value/Gross Profit9.92
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$4.00Price Target Upside8.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Daré Bioscience News
PremiumCompany Announcements
Daré Bioscience Regains Nasdaq Compliance, Advances Phase 3 Trials
PremiumCompany Announcements
Daré Bioscience Executes 1-for-12 Reverse Stock Split
PremiumPress Releases
Daré Bioscience Announces Reverse Stock Split
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe pivotal study for Ovaprene is nearly fully funded and enrollment is expected to finish in 2H24.
FundingCash runway was extended into 2025 by previously announced royalty financing with XOMA.
Product DevelopmentOvaprene could be a blockbuster contraceptive device given the lack of convenient non-hormonal products on the market.
Bears Say
Clinical Trial ResultsSildenafil Cream did not achieve statistical significance for the co-primary endpoints related to the SFQ28 arousal sensation domain and FSDS-DAO survey.
Regulatory PathwaySildenafil cream opportunity is exciting, but still not de-risked due to uncertainty around regulatory pathway and lack of significant results on most Ph2 endpoints.
Revenue PerformanceDaré recorded total revenue of $9.3K from license, milestone, and royalty income, below the estimate and street consensus of $0.5M.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $3.05 and its highest was $13.58 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Currently, no data Available
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Aug 08, 2024 which is in 16 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on May 14, 2024. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.72 by -$0.12.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -$0.04.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 8,424,408 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.72. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Daré Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (8.55% Upside)
$4.00 (8.55% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-57.15%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
---
DARE Earnings Call
Q1 2024
0:00 / 0:00
---
DARE Stock 12 Month Forecast
Average Price Target
$4.00
▲(8.55% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
7/23 ratings generated profit
1 Year Average Return
-4.95%
reiterated a buy rating 11 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of -4.95% per trade.
---